By Nigam Arora & Dr. Natasha Arora
VFC is long from $13.33. It is trading at $26.93 as of this writing, representing a 102% gain.
VFC was bought when the stock was hated and Wall Street was mercilessly selling VFC. This demonstrates the power of contrary investing.
Buyout Target
VFC remains a buyout target.
To date, 201 Arora Portfolio companies have been bought out, producing a fortune for members who consistently invest in buyout targets.
As always, there is no guarantee of a buyout.
Target Zone
VFC entered the target zone, which has been $28 – $32.
The new target zone is *** (To see the locked content, please take a 30 day free trial).
What To Do Now
Those in the stock may consider taking partial profits and continuing to hold the remaining.
Those not in the stock may consider waiting for a new signal.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.

Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.

Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.